Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

8.50
+0.26003.16%
Volume:538.32K
Turnover:4.54M
Market Cap:428.30M
PE:-2.74
High:8.56
Open:8.33
Low:8.28
Close:8.24
Loading ...

REGENXBIO Announces Promising Preclinical Results for RGX-202 Gene Therapy in Treating Duchenne Muscular Dystrophy, Highlighting Potential for Improved Patient Outcomes

Reuters
·
10 Jul

RBC Capital Remains a Buy on RegenXBio (RGNX)

TIPRANKS
·
08 Jul

RBC Cuts Price Target on REGENXBIO to $21 From $25, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jul

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. -- Barrons.com

Dow Jones
·
20 Jun

Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. -- Barrons.com

Dow Jones
·
19 Jun

BofA expects no changes for Regenxbio regimen after competitor safety issue

TIPRANKS
·
17 Jun

Regenxbio files to sell 268,096 shares of common stock for holders

TIPRANKS
·
14 Jun

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
09 Jun

Raymond James Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
06 Jun

Crude Oil Moves Higher; Ciena Posts Downbeat Earnings

Benzinga
·
06 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle

Reuters
·
06 Jun

BUZZ-U.S. STOCKS ON THE MOVE-PVH, Phio Pharma, Cracker Barrel

Reuters
·
05 Jun

Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial

TIPRANKS
·
05 Jun

Regenxbio Inc. Announces Positive Interim Data from Phase I/II Trial of RGX-202 for Duchenne Muscular Dystrophy

Reuters
·
05 Jun

Regenxbio Inc - Pivotal Trial Expected to Support Bla Submission Using Accelerated Approval Pathway in Mid-2026

THOMSON REUTERS
·
05 Jun

Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial of Rgx-202

THOMSON REUTERS
·
05 Jun

Regenxbio Inc - Favorable Safety Profile Continues With No Serious Adverse Events Observed in Rgx-202 Trial

THOMSON REUTERS
·
05 Jun

Regenxbio Inc -Expects to Share Top-Line Data in First Half of 2026

THOMSON REUTERS
·
05 Jun

Regenxbio Inc. Conducted Annual Stockholders Meeting

Reuters
·
04 Jun

Regenxbio Inc. to Release Interim Functional Data from Phase I/II AFFINITY DUCHENNE® Trial

Reuters
·
02 Jun